Citigroup upgraded Biogen Idec (NASDAQ: BIIB ) from Neutral to Buy and raised the price target from $160.00 to $187.00. Citigroup commented, "We are upgrading Biogen to Buy as we simply do not see a better entry point anytime soon. We have been on the sidelines hoping to find material